Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Myriad Genetics, Inc. - MYGN

GlobeNewswire August 14, 2019

Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2019 Financial Results

GlobeNewswire August 13, 2019

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer

GlobeNewswire August 7, 2019

Myriad to Announce Fiscal Fourth-Quarter 2019 Financial Results on August 13, 2019

GlobeNewswire August 6, 2019

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer

GlobeNewswire June 27, 2019

Myriad Announces Publication of First Comprehensive Economic Study Demonstrating Cost Effectiveness of EndoPredict® for Breast Cancer

GlobeNewswire June 25, 2019

Myriad Genetics Receives Second Insurance Reimbursement Decision for its BRACAnalysis® Diagnostic System in Japan

GlobeNewswire June 19, 2019

Myriad Genetics to Present at the 2019 Goldman Sachs Global Healthcare Conference

GlobeNewswire June 5, 2019

Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology

GlobeNewswire June 3, 2019

BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)

GlobeNewswire June 2, 2019

Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting

GlobeNewswire May 14, 2019

New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy

GlobeNewswire May 9, 2019

Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results

GlobeNewswire May 7, 2019

Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight®

GlobeNewswire May 1, 2019

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

GlobeNewswire May 1, 2019

EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer

GlobeNewswire April 30, 2019

Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019

GlobeNewswire April 23, 2019

Myriad to Present Multiple Women's Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting

GlobeNewswire April 23, 2019

Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council's 2019 Shatter List

GlobeNewswire April 17, 2019

26 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  April 10, 2019